Ronald C Renaud JR
CIK 1354434 · CEO & President · last filed 2026-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TBIO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
60 HAMPSHIRE STREET
CAMBRIDGE, MA 02109
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| UPB | Director | — | $2.88 | — | $0 | 3 | 2026-06-11 |
| KLRA | CEO & President | 38,094 | $12.88 | $490.5K | $0 | 2 | 2026-06-11 |
| Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | President & CEO | 244,309 | $44.96 | $10.98M | $2.01M | 4 | 2024-01-23 |
| ATRA | Director | 1,260 | $8.14 | $10.3K | $0 | 3 | 2022-06-27 |
| ImageneBio, Inc. (IKNA) Delisted | Director | — | $17.16 | — | $0 | 2 | 2022-06-13 |
| Translate Bio, Inc. (TBIO) Delisted | Chief Executive Officer | 0 | $0.00 | $0 | -$36.25M | 9 | 2021-09-14 |
| CHIMERIX INC (CMRX) Delisted | Director | — | $8.54 | — | $0 | 6 | 2019-06-24 |
| AKBA | Director | 5,000 | $0.68 | $3.4K | $59.6K | 6 | 2018-06-15 |
| PTCT | Director | — | $61.18 | — | $0 | 3 | 2017-01-05 |
| IDENIX PHARMACEUTICALS INC (IDIX) Delisted | President & CEO | 89,990 | — | — | $0 | 14 | 2014-08-05 |
| KERYX BIOPHARMACEUTICALS INC (KERX) Delisted | Chief Financial Officer | 94,027 | — | — | $0 | 2 | 2007-02-16 |
Recent Filings · Page 3 of 6
55 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-04-30 | ATRA | Grant (A) | — | $0 | EDGAR |
| 2020-03-05 | Translate Bio, Inc. (TBIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-24 | CHIMERIX INC (CMRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-03-12 | Translate Bio, Inc. (TBIO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-07-03 | Translate Bio, Inc. (TBIO) Delisted | Conv (C) | +81,818 | $0 | EDGAR |
| 2018-06-21 | CHIMERIX INC (CMRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-15 | AKBA | Grant (A) | — | $0 | EDGAR |
| 2017-06-29 | CHIMERIX INC (CMRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-19 | AKBA | Grant (A) | — | $0 | EDGAR |
| 2017-01-05 | PTCT | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.